Skip to main content
. 2020 Jun 14;12(6):1574. doi: 10.3390/cancers12061574

Figure 2.

Figure 2

Genetic validation of XPO1 as a cotarget with FLT3. (a) Design of three guides targeting XPO1 used to knock down XPO1 expression in MOLM-13 cells. (b) Immunoblot analysis showing protein expression of XPO1 in MOLM-13 cells, XPO1 knockdown (KD) cell lines, and HG3 (positive control). (c) MOLM-13 parent cells and XPO1 knockdown cells were treated with 10 nM midostaurin or 8 nM gilteritinib for 48 h and proliferation changes compared. For each knockdown experiment, conditions were compared with each clone separately and then the results pooled together across clones to get an average effect (p < 0.001 where noted).